JA2-WP5 EUnetHTA Joint Action 2 (2012-15)
2015 - PDF

The purpose of the assessment is to address the research question whether the use of the technologies in question is more effective and/or safer than their comparators, which were chosen based on CE mark indications, recommendations in clinical guidelines for the treatment of MR and EUnetHTA guidelines.

Final version of the assessment was published in September 2015

Below is the documentation provided by the Joint Assessment authoring team: